Drug intelligence / Profile preview

MTS-101

Development stage: Unknown
Lead developer: Metsera
Modality: Peptides

Overview

MTS-101 is a Phase 2b dual agonist targeting both the Glucagon-like peptide 1 receptor (GLP-1R) and the Glucagon receptor (GCGR). Developed by Metsera, this drug is being investigated for the treatment of obesity and type 2 diabetes, aiming to modulate glucose metabolism and appetite. Its significance is highlighted by acquisition bids from major pharmaceutical companies like Pfizer and Novo Nordisk.

Targets

GCGR (Glucagon receptor)GLP1R (GLP-1R)

Beyond the preview

Go deeper on MTS-101.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MTS-101.

Explore the full profile